Clariant Scores Legal Win and Lifts Savings Program as Middle East Drags Persist
Amsterdam court dismisses Shell's ethylene claim, clearing a decade-long overhang, while the company raises its cost-out target and maintains 18% EBITDA margin guidance.
CLN.SW · Earnings Call · 2026-07-31
A Court Victory That Reshapes the Risk Map
When Clariant reported Q2 2026 results on July 31, the market reaction was less about the numbers and more about a legal milestone announced hours earlier. The Amsterdam District Court dismissed Shell's ethylene damage claim in its entirety, alongside a related claim by Stichting Ethylene Claims. CEO Conrad Keijzer framed it as a pivotal moment:
We welcome the decision by the Amsterdam District Court to dismiss the ethylene damage claim brought by Shell in its entirety against ourselves and 3 other defendants, which related to the 2020 competition law infringement.
The ruling directly addresses a keyword that has trailed Clariant for years — Amsterdam District Court and the broader Shell case — and removes a substantial overhang on the share price. As Keijzer noted in the Q&A: “There was a overhang on our share price from these ethylene cartel cases, which we have argued all the time.” — Conrad Keijzer, CEO · 2026-07-31
The company had consistently rejected the claims, and prior calls echoed the same defensive posture. In October 2025, Keijzer asserted: “We do have substantiated economic evidence that shows that the conduct of the parties did not produce any effect on the market.” — Conrad Keijzer, CEO · 2025-08-01 That position has now been validated in court, providing a tangible de-risking event for shareholders.
Middle East Fallout and the Catalysts Drag
The Middle East conflict remains the single largest operational headwind. During the quarter, Catalysts volumes fell 14.2% year-on-year, with roughly two-thirds of that decline attributable to order delays linked to the conflict. The company also saw a global spike in force majeures — rising above 100 in May–June before easing to below 100 in July. Keijzer provided context on the recovery: “If you now look at the July number, we're below 100 force majeures globally. We see an easing outside the Middle East.” — Conrad Keijzer, CEO · 2026-07-31
This trend is partially echoed in the global force majeure theme, which surged in the sector. For Clariant, the impact was most acute in Catalysts, but the company leveraged its global footprint to mitigate supply disruptions. The CFO highlighted that despite the volume hit, Catalysts maintained an 18.6% EBITDA margin, down from an elevated 22.3% last year but still resilient given the circumstances.
Cost Discipline and the Path to 2027
In response to the ongoing conflict and raw material inflation, Clariant raised its performance improvement program savings target by CHF 20 million, now targeting CHF 100 million in run-rate savings by 2027. The company booked CHF 24 million in restructuring charges in Q2, with the bulk of costs now behind it. This disciplined approach underpins the unchanged guidance of around 18% EBITDA margin for 2026.
Care Chemicals was the star performer, delivering a 310 basis point margin improvement to 20.7% on strong pricing and underlying volume growth, despite a modest drag from customer prebuying in cosmetics. As Keijzer explained, “what we basically saw is very limited prebuying, where we did see some of it in Care Chemicals was in our cosmetics business.” — Conrad Keijzer, CEO · 2026-07-31
The confidence in forward momentum is evident. Keijzer reiterated, “We are actually quite confident about the guidance for the year.” — Conrad Keijzer, CEO · 2026-07-31 This echoes the strategic repositioning that has been underway for years; as he said in the February 2026 call: “If you look at the recent years, we've really repositioned the business to become fully specialty.” — Conrad Keijzer, CEO · 2026-02-26
With the legal overhang lifting and cost programs accelerating, Clariant enters the second half with a cleaner risk profile and a clear path toward its 2027 medium-term targets of 19%–21% EBITDA margins. The Crop Solutions recovery and the easing of Middle East disruptions could provide the incremental volume needed to hit the upper end of guidance. For now, the market's focus is squarely on execution — and on whether the court victory finally marks the end of the ethylene saga.